Orpea SA (FR:EMEIS)
:EMEIS
Top Page
Orpea SA
(EMEIS)
Select Model
Select Model
Rating:51Neutral
Price Target:
€14.50
▲(3.42% Upside)
Action:ReiteratedDate:11/11/25
The overall score of 51 reflects a cautious outlook for FR:EMEIS, driven primarily by weak financial performance with ongoing losses and high debt levels. Positive earnings call highlights, including revenue growth and debt reduction, provide some optimism, while technical indicators suggest a neutral trend. Valuation concerns due to negative earnings further temper the score.
Positive Factors
Revenue Growth
Consistent revenue growth indicates strong market demand and effective pricing strategies, enhancing long-term business sustainability.
Negative Factors
Negative Net Income
Persistent negative net income indicates ongoing profitability challenges, which can hinder long-term financial sustainability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth indicates strong market demand and effective pricing strategies, enhancing long-term business sustainability.
Read all positive factors
Orpea SA (EMEIS) vs. iShares MSCI France ETF (EWQ)
Market Cap
€2.21B
Dividend YieldN/A
Average Volume (3M)485.78K
Price to Earnings (P/E)―
Beta (1Y)1.44
Revenue Growth6.30%
EPS Growth-100.37%
CountryFR
Employees51,071
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.85
Shares Outstanding161,440,050
10 Day Avg. Volume432,757
30 Day Avg. Volume485,783
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.55
Price to Sales (P/S)0.17
P/FCF Ratio2.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.00Price Target Upside-28.67% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)-0.8
Revenue Forecast (FY)€6.12B
Orpea SA Business Overview & Revenue Model
Company Description
emeis Société anonyme operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals. Its nursing home facilities provide personalized support services; and logistical and residential service...
How the Company Makes Money
Orpea generates revenue primarily through the operation of its healthcare facilities, which receive payments from residents, their families, and public health insurers. The company’s business model relies on a combination of private pay and public...
Orpea SA Earnings Call Summary
Earnings Call Date:Sep 30, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:May 08, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant achievements in revenue growth, occupancy rates, and successful disposals, leading to reduced net debt and positive cash flow. However, challenges remain with negative net income, a high leverage ratio, and difficulties in the Irish market.Positive Updates
Strong Revenue Growth
The company reported an organic revenue growth of 6.2%, driven by a price effect of 3.4% and an occupancy rate effect of 1.8%.
Negative Updates
Negative Net Income
Despite improvements, the company still reported a negative net income, although losses have been reduced by EUR 120 million.
Read all updates
Q2-2025 Updates
Positive
Negative
Strong Revenue Growth
The company reported an organic revenue growth of 6.2%, driven by a price effect of 3.4% and an occupancy rate effect of 1.8%.
Read all positive updates
Company Guidance
In the recent conference call, MA's management team provided an optimistic outlook for the company's financial performance and strategic initiatives. Key metrics highlighted include a significant improvement in occupancy rates, now nearing 88% on mature perimeters, and a solid organic revenue growth of 6.2% in the first half of 2025. The company reported a 29.5% increase in EBITDA, achieving a like-for-like growth of 79%. Additionally, MA has significantly exceeded its disposal target, securing EUR 2.1 billion since mid-2022, which is expected to materially strengthen its financial structure by reducing net debt and improving the leverage ratio. The management confirmed their midterm outlook, projecting a CAGR of 4% to 5% in revenues and 12% to 16% in EBITDA from 2024 to 2028. They also detailed a new real estate partnership expected to generate EUR 761 million in cash, further enhancing liquidity and financial resilience.Orpea SA Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
20
Very Negative
Cash Flow
45
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.32B | 5.64B | 5.20B | 4.68B | 4.30B | 3.92B |
| Gross Profit | 570.61M | 4.51B | 655.93M | 713.73M | 922.68M | 963.25M |
| EBITDA | 793.42M | 731.55M | 2.80B | -3.45B | 646.07M | 637.64M |
| Net Income | -223.50M | -412.06M | 1.35B | -4.03B | 65.19M | 160.05M |
Balance Sheet | ||||||
| Total Assets | 13.15B | 13.41B | 13.91B | 14.49B | 17.07B | 16.97B |
| Cash, Cash Equivalents and Short-Term Investments | 376.00M | 518.72M | 692.95M | 902.99M | 957.70M | 894.13M |
| Total Debt | 7.68B | 8.86B | 9.16B | 13.38B | 12.25B | 10.77B |
| Total Liabilities | 11.57B | 11.69B | 12.02B | 16.00B | 14.74B | 13.48B |
| Stockholders Equity | 1.59B | 1.72B | 1.89B | -1.50B | 2.32B | 3.50B |
Cash Flow | ||||||
| Free Cash Flow | 170.72M | 328.61M | 216.90M | 244.74M | 331.85M | 283.29M |
| Operating Cash Flow | 365.88M | 472.05M | 366.14M | 409.73M | 753.75M | 777.73M |
| Investing Cash Flow | -103.69M | -140.43M | -318.17M | -657.49M | -1.41B | -1.01B |
| Financing Cash Flow | -456.50M | -458.08M | -259.44M | 151.81M | 718.30M | 285.80M |
Orpea SA Technical Analysis
Positive
14.02
Price Trends
14.08
Negative
13.85
Negative
13.37
Positive
Market Momentum
-0.28
Negative
50.54
Neutral
77.37
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:EMEIS, the sentiment is Positive. The current price of 14.02 is above the 20-day moving average (MA) of 13.59, below the 50-day MA of 14.08, and above the 200-day MA of 13.37, indicating a neutral trend. The MACD of -0.28 indicates Negative momentum. The RSI at 50.54 is Neutral, neither overbought nor oversold. The STOCH value of 77.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:EMEIS.
Orpea SA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | €289.68M | 10.41 | 6.64% | 2.73% | 13.31% | -13.07% | |
64 Neutral | €570.78M | 10.15 | 16.40% | 2.85% | 4.45% | -14.08% | |
60 Neutral | €1.13B | -7.25 | -4.36% | ― | 4.70% | -0.37% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | €11.77B | 23.65 | 11.27% | 0.97% | 6.25% | 18.93% | |
51 Neutral | €2.21B | -6.61 | -13.50% | ― | 6.30% | -100.37% | |
47 Neutral | €1.32B | 873.33 | -1.70% | ― | 1.98% | 85.87% |
* General Sector Average
FR:EMEIS
Orpea SA
13.70
3.55
34.95%
FR:ERF
Eurofins Scientific
66.90
21.41
47.07%
FR:CLARI
Clariane
3.69
0.09
2.44%
FR:LNA
LNA Sante SA
27.80
7.03
33.85%
FR:EQS
Equasens
38.00
5.84
18.16%
FR:GDS
Ramsay Generale de Sante
10.25
0.63
6.55%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.